Trial Profile
Switch from ARB Combination Tablets to Azilsartan: Clinical research on organ protective effect in hypertensive patients living in Okayama
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2014
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms MAGENTA
- 18 Jun 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 21 Dec 2013 New trial record